Announcements
- Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
- District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
- Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
- Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
- Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
- Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
- Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
- Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
As of last trade Liquidia Corp (LT4:DUS) traded at 10.29, 5.48% above its 52-week low of 9.76, set on Jul 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.23 |
---|---|
High | 10.29 |
Low | 10.22 |
Bid | 10.54 |
Offer | 10.86 |
Previous close | 10.31 |
Average volume | 0.00 |
---|---|
Shares outstanding | 76.38m |
Free float | 60.01m |
P/E (TTM) | -- |
Market cap | 865.80m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 15:30 BST.
More ▼